HBM Healthcare Investments holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).
Facts & Figures (CHF)
as of 31.5.2021
- Total Assets 2'308 m
- Net Assets (NAV) 2'146m
- Share Price 341.00
- NAV per share 308.48
- Number of issued shares 6.96 million
- Number of shareholders 3'600
ESG/SDG
ESG means using Environmental, Social and Governance factors to evaluate companies and countries on how far advanced they are with sustainability. SDG is a newer sustainability scoring concept initiated in 2015, which has been driven by the Division for Sustainable Development Goals (DSDG) in the United Nations Department of Economic and Social Affairs (UNDESA).
HBMs strategy is by its very nature optimally aligned with the goals of ESG and SDG
By investing solely in companies within the healthcare sector, HBM specifically provides funds to innovative young firms developing groundbreaking therapies that have the potential to improve the health and wellbeing of people around the globe. HBM generally invests in development stage companies, which are often exclusively engaged in R&D, as many of them do not have products on the market. Carbon emissions and the use of natural resources are typically low. Accordingly, their negative impact on the environment is limited. On the other hand, such firms have a positive impact on society by creating jobs and providing a dynamic and modern working environment with equal rights and opportunities for their employees.